Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 136 articles: HTML format Text format

Single Articles

August 2018
1. SONG KA, Hosono Y, Turner C, Jacob S, et al
   Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target.
   Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-0304.
   PubMed     Text format     Abstract available
   
   
   
2. KIM ES, Kelly K, Paz-Ares L, Garrido P, et al
   Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study.
   Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0651.
   PubMed     Text format     Abstract available
   
   
   
3. BAHCALL M, Awad MM, Sholl LM, Wilson FH, et al
   Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer.
   Clin Cancer Res. 2018 Aug 2. pii: 1078-0432.CCR-18-0876.
   PubMed     Text format     Abstract available
   
   
   
4. WANG Y, Li N, Jiang W, Deng W, et al
   Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer.
   Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-1489.
   PubMed     Text format     Abstract available
   
   
   July 2018
5. PONATH P, Menezes DL, Pan C, Chen B, et al
   A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer.
   Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0018.
   PubMed     Text format     Abstract available
   
   
   
6. AKIBA T, Morikawa T, Odaka M, Nakada T, et al
   Vitamin D supplementation and survival of patients with non-small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.
   Clin Cancer Res. 2018 Jul 17. pii: 1078-0432.CCR-18-0483.
   PubMed     Text format     Abstract available
   
   
   
7. ROMANIELLO D, Mazzeo L, Mancini M, Marrocco I, et al
   A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.
   Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0450.
   PubMed     Text format     Abstract available
   
   
   June 2018
8. LI S, Liu S, Deng J, Akbay EA, et al
   Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer.
   Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3438.
   PubMed     Text format     Abstract available
   
   
   
9. KO EC, Raben D, Formenti SC
   The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3620.
   PubMed     Text format     Abstract available
   
   
   
10. LAIRD JH, Lok BH, Ma J, Bell A, et al
    Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0401.
    PubMed     Text format     Abstract available
    
    
    
11. LALLO A, Frese KK, Morrow C, Szczepaniak Sloane R, et al
    The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-2805.
    PubMed     Text format     Abstract available
    
    
    
12. SAIGI M, Alburquerque-Bejar JJ, McLEER-Florin A, Pereira C, et al
    MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer.
    Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-18-0267.
    PubMed     Text format     Abstract available
    
    
    May 2018
13. BAUML J, Levy B
    Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer.
    Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-18-0969.
    PubMed     Text format     Abstract available
    
    
    
14. HIGGS BW, Morehouse C, Streicher KL, Brohawn P, et al
    Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small-Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3451.
    PubMed     Text format     Abstract available
    
    
    
15. NAZ S, Sowers AL, Choudhuri R, Wissler MF, et al
    Abemaciclib, a Selective CDK4/6 Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in vitro and in vivo.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3575.
    PubMed     Text format     Abstract available
    
    
    April 2018
16. CLARET L, Jin JY, Ferte C, Winter H, et al
    A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3662.
    PubMed     Text format     Abstract available
    
    
    
17. MCCOACH CE, Le A, Gowan K, Jones KL, et al
    Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2452.
    PubMed     Text format     Abstract available
    
    
    
18. IOMMELLI F, De Rosa V, Terlizzi C, Monti M, et al
    Inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer detected by 18F-fluorothymidine.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3657.
    PubMed     Text format     Abstract available
    
    
    
19. FRANK R, Scheffler M, Merkelbach-Bruse S, Ihle MA, et al
    Clinical and pathological characteristics of KEAP1- and NFE2L2- mutated non-small cell lung carcinoma (NSCLC).
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3416.
    PubMed     Text format     Abstract available
    
    
    March 2018
20. MCCOACH CE, Blakely CM, Banks KC, Levy BM, et al
    Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2588.
    PubMed     Text format     Abstract available
    
    
    
21. HORN L, Infante JR, Reckamp KL, Blumenshein GR, et al
    Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2398.
    PubMed     Text format     Abstract available
    
    
    
22. CASTELLANOS-RIZALDOS E, Grimm DG, Tadigotla V, Hurley J, et al
    Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3369.
    PubMed     Text format     Abstract available
    
    
    
23. YANG Z, Yang N, Ou Q, Xiang Y, et al
    Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-2310.
    PubMed     Text format     Abstract available
    
    
    
24. CAPPUZZO F, Landi L
    HER2 deregulation in lung cancer: right time to adopt an orphan?
    Clin Cancer Res. 2018 Mar 1. pii: 1078-0432.CCR-18-0198.
    PubMed     Text format     Abstract available
    
    
    February 2018
25. BILLATOS E, Vick JL, Lenburg ME, Spira AE, et al
    The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-16-3187.
    PubMed     Text format     Abstract available
    
    
    
26. TIAN Y, Wang Z, Liu X, Duan J, et al
    Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2855.
    PubMed     Text format     Abstract available
    
    
    
27. YU J, Wang S, Zhao W, Duan J, et al
    Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel alpha2delta1 subunit-mediated chemotherapy resistance in small cell lung cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-1932.
    PubMed     Text format     Abstract available
    
    
    
28. MACLEOD AK, Lin, Huang JT, McLaughlin LA, et al
    Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3555.
    PubMed     Text format     Abstract available
    
    
    January 2018
29. MCCALL NS, Dicker AP, Lu B
    Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3269.
    PubMed     Text format     Abstract available
    
    
    
30. KITAJIMA S, Barbie DA
    RASA1/NF1 mutant lung cancer: Racing to the clinic?
    Clin Cancer Res. 2018 Jan 17. pii: 1078-0432.CCR-17-3597.
    PubMed     Text format     Abstract available
    
    
    
31. GOLDBERG SB, Narayan A, Kole AJ, Decker RH, et al
    Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Clin Cancer Res. 2018 Jan 12. pii: 1078-0432.CCR-17-1341.
    PubMed     Text format     Abstract available
    
    
    
32. THANGAVEL C, Boopathi E, Liu Y, McNair C, et al
    Therapeutic Challenge With a CDK 4/6 Inhibitor Induces an RB-dependent SMAC Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2074.
    PubMed     Text format     Abstract available
    
    
    
33. LIU S, Li S, Hai J, Wang X, et al
    Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
    Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-1875.
    PubMed     Text format     Abstract available
    
    
    December 2017
34. YE M, Zhang Y, Gao H, Xu Y, et al
    Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small-Cell Lung Cancer by Activating Src-Mediated Bypass Signaling.
    Clin Cancer Res. 2017 Dec 11. pii: 1078-0432.CCR-17-0396.
    PubMed     Text format     Abstract available
    
    
    
35. AISNER DL, Sholl LM, Berry L, Rossi M, et al
    The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).
    Clin Cancer Res. 2017 Dec 7. pii: 1078-0432.CCR-17-2289.
    PubMed     Text format     Abstract available
    
    
    
36. WANG Q, Zeng F, Sun Y, Qiu Q, et al
    Etk interaction with PFKFB4 modulates chemoresistance of small cell lung cancer by regulating autophagy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1475.
    PubMed     Text format     Abstract available
    
    
    
37. VILLARROEL-ESPINDOLA F, Yu X, Datar I, Mani N, et al
    Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2542.
    PubMed     Text format     Abstract available
    
    
    October 2017
38. ARBOUR KC, Jordan EJ, Kim HR, Dienstag J, et al
    Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 31. pii: clincanres.1841.2017.
    PubMed     Text format     Abstract available
    
    
    
39. FABER AC, Song KA, Niederst MJ, Lochmann TL, et al
    Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.
    Clin Cancer Res. 2017 Oct 19. pii: clincanres.1577.2017.
    PubMed     Text format     Abstract available
    
    
    
40. FAN Y, Zhu X, Xu Y, Lu X, et al
    Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
    PubMed     Text format     Abstract available
    
    
    
41. WANG Y, Gudikote J, Giri U, Yan J, et al
    RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1455.2017.
    PubMed     Text format     Abstract available
    
    
    
42. LOHAVANICHBUTR P, Sakoda LC, Amos CI, Arnold SM, et al
    Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.1401.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
43. HU X, Liu T, Wu X, Chen T, et al
    Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/beta-catenin signaling.
    Clin Cancer Res. 2017 Sep 28. pii: clincanres.1169.2017.
    PubMed     Text format     Abstract available
    
    
    
44. YI JS, Ready N, Healy P, Dumbauld C, et al
    Immune Activation in Early Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.2005.2017.
    PubMed     Text format     Abstract available
    
    
    
45. FENG Y, Wang X, Bajaj G, Agrawal S, et al
    Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017;23:5394-5405.
    PubMed     Text format     Abstract available
    
    
    
46. GU L, Deng JZ, Roy S, Hammond PT, et al
    A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-small Cell Lung Cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.2186.2016.
    PubMed     Text format     Abstract available
    
    
    August 2017
47. OOKI A, Maleki Z, Tsay JJ, Goparaju CM, et al
    A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.1222.2017.
    PubMed     Text format     Abstract available
    
    
    
48. 
    Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
    Clin Cancer Res. 2017;23:4523.
    PubMed     Text format    
    
    
    
49. ENGSTROM L, Aranda R, Lee M, Tovar EA, et al
    Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.1192.2017.
    PubMed     Text format     Abstract available
    
    
    July 2017
50. SEN T, Tong P, Diao L, Li L, et al
    Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer.
    Clin Cancer Res. 2017 Jul 11. pii: clincanres.1284.2017.
    PubMed     Text format     Abstract available
    
    
    
51. GRAY JE, Heist RS, Starodub AN, Camidge DR, et al
    Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0933.2017.
    PubMed     Text format     Abstract available
    
    
    
52. NISHINO M, Dahlberg SE, Adeni AE, Lydon C, et al
    Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.1434.2017.
    PubMed     Text format     Abstract available
    
    
    
53. ADAMS DL, Adams DK, He J, Kalhor N, et al
    Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0802.2017.
    PubMed     Text format     Abstract available
    
    
    June 2017
54. MALCHERS F, Ercanoglu MS, Schutte D, Castiglione R, et al
    Mechanisms of primary drug resistance in FGFR1 amplified lung cancer.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0478.2017.
    PubMed     Text format     Abstract available
    
    
    
55. WEINSTOCK C, Khozin S, Suzman D, Zhang L, et al
    U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0540.2017.
    PubMed     Text format     Abstract available
    
    
    
56. JIN X, Chen Y, Chen H, Fei S, et al
    Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early stage non-small-cell lung cancer using next-generation sequencing.
    Clin Cancer Res. 2017 Jun 12. pii: clincanres.0577.2017.
    PubMed     Text format     Abstract available
    
    
    May 2017
57. CASCONE T, Xu L, Lin HY, Liu W, et al
    The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer.
    Clin Cancer Res. 2017 May 30. pii: clincanres.3216.2016.
    PubMed     Text format     Abstract available
    
    
    
58. JEONG J, Oh JH, Sonke JJ, Belderbos JSA, et al
    Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.
    Clin Cancer Res. 2017 May 24. pii: clincanres.3277.2017.
    PubMed     Text format     Abstract available
    
    
    
59. LEE JMM, Lee MH, Garon E, Goldman JW, et al
    Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration.
    Clin Cancer Res. 2017 May 3. pii: clincanres.2821.2016.
    PubMed     Text format     Abstract available
    
    
    April 2017
60. COOPER WA, Russell PA, Cherian M, Duhig EE, et al
    Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC).
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0151.2017.
    PubMed     Text format     Abstract available
    
    
    
61. LI AN, Yang J, Zhang XC, Zhang Z, et al
    Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer.
    Clin Cancer Res. 2017 Apr 10. pii: clincanres.3273.2016.
    PubMed     Text format     Abstract available
    
    
    March 2017
62. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
    Clin Cancer Res. 2017 Mar 16. doi: 10.1158/1078-0432.CCR-16-1946.
    PubMed     Text format     Abstract available
    
    
    
63. TANG C, Welsh JW, de Groot P, Massarelli E, et al
    Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
    Clin Cancer Res. 2017;23:1388-1396.
    PubMed     Text format     Abstract available
    
    
    
64. BRANT R, Sharpe A, Liptrot T, Dry JR, et al
    Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
    Clin Cancer Res. 2017;23:1471-1480.
    PubMed     Text format     Abstract available
    
    
    
65. LIU Y, Balagurunathan Y, Atwater T, Antic S, et al
    Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules.
    Clin Cancer Res. 2017;23:1442-1449.
    PubMed     Text format     Abstract available
    
    
    
66. SCARBOROUGH HA, Helfrich BA, Casas-Selves M, Schuller AG, et al
    AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
    Clin Cancer Res. 2017;23:1531-1541.
    PubMed     Text format     Abstract available
    
    
    
67. KURZROCK R, Stewart DJ
    Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Clin Cancer Res. 2017;23:1137-1148.
    PubMed     Text format     Abstract available
    
    
    February 2017
68. LAKSHMANAN I, Salfity S, Seshacharyulu P, Rachagani S, et al
    MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.2530.2016.
    PubMed     Text format     Abstract available
    
    
    
69. VAN DER WEKKEN A, Pelgrim R, 't Hart N, Werner N, et al
    Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer.
    Clin Cancer Res. 2017 Feb 9. pii: clincanres.1631.2016.
    PubMed     Text format     Abstract available
    
    
    January 2017
70. BONANNO L, De Paoli A, Zulato E, Esposito G, et al
    LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab.
    Clin Cancer Res. 2017 Jan 24. pii: clincanres.2410.2016.
    PubMed     Text format     Abstract available
    
    
    
71. RATCLIFFE MJ, Sharpe A, Midha A, Barker C, et al
    Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2375.2016.
    PubMed     Text format     Abstract available
    
    
    
72. DAMA E, Melocchi V, Dezi F, Pirroni S, et al
    An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
    Clin Cancer Res. 2017;23:62-72.
    PubMed     Text format     Abstract available
    
    
    December 2016
73. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    GENOMIC PROFILING OF PATIENT-DERIVED XENOGRAFTS FOR LUNG CANCER IDENTIFIES B2M INACTIVATION IMPAIRING IMMUNORECOGNITION.
    Clin Cancer Res. 2016 Dec 21. pii: clincanres.1946.2016.
    PubMed     Text format     Abstract available
    
    
    
74. TANIMOTO A, Takeuchi S, Arai S, Fukuda K, et al
    Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib-resistance in EGFR-mutant lung cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2271.2016.
    PubMed     Text format     Abstract available
    
    
    
75. XUE Y, Lito P
    Predicting MEK inhibitor response in lung cancer: a proper signature is required.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.2576.2016.
    PubMed     Text format     Abstract available
    
    
    
76. KHOZIN S, Weinstock C, Blumenthal GM, Cheng J, et al
    Osimertinib for the Treatment of Metastatic Epidermal Growth Factor T970M Positive Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1773.2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
77. LIU G, Cuffe S, Liang S, Azad AK, et al
    BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1640.2016.
    PubMed     Text format     Abstract available
    
    
    
78. SKOULIDIS F, Papadimitrakopoulou VA
    Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-small Cell Lung Cancer.
    Clin Cancer Res. 2016 Nov 7. pii: clincanres.2815.2015.
    PubMed     Text format     Abstract available
    
    
    
79. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available
    
    
    
80. SKOULIDIS F, Papadimitrakopoulou VA
    Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.
    Clin Cancer Res. 2016;22:5177-5182.
    PubMed     Text format     Abstract available
    
    
    October 2016
81. HULBERT A, Jusue Torres I, Stark A, Chen C, et al
    Early Detection of Lung Cancer using DNA Promoter Hypermethylation in Plasma and Sputum.
    Clin Cancer Res. 2016 Oct 11. pii: clincanres.1371.2016.
    PubMed     Text format     Abstract available
    
    
    
82. RAMALINGAM SS, Blais N, Mazieres J, Reck M, et al
    Randomized, Placebo-Controlled, Phase 2 Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.3069.2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
83. GEORGE J, Saito M, Tsuta K, Iwakawa R, et al
    Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.1069.2016.
    PubMed     Text format     Abstract available
    
    
    
84. THOMPSON JC, Yee SS, Troxel AB, Savitch SL, et al
    Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1231.2016.
    PubMed     Text format     Abstract available
    
    
    
85. ZHOU W, Xu J, Li H, Xu M, et al
    Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage.
    Clin Cancer Res. 2016 Sep 2. pii: clincanres.1585.2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
86. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.3071.2015.
    PubMed     Text format     Abstract available
    
    
    
87. MECKLENBURG I, Sienel W, Schmid S, Passlick B, et al
    A threshold of systemic MAGE-A gene expression predicting survival in resected non-small cell lung cancer.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.0557.2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
88. GETTINGER S, Politi K
    PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer: Lost cause?
    Clin Cancer Res. 2016 Jul 28. pii: clincanres.1401.2016.
    PubMed     Text format     Abstract available
    
    
    
89. LOK BH, Gardner EE, Schneeberger VE, Ni A, et al
    PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.1040.2016.
    PubMed     Text format     Abstract available
    
    
    
90. SCHALPER KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, et al
    Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0150.2016.
    PubMed     Text format     Abstract available
    
    
    
91. BALLARD P, Yates JW, Yang Z, Kim DW, et al
    Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
    PubMed     Text format     Abstract available
    
    
    
92. LARKINS E, Blumenthal GM, Chen H, He K, et al
    FDA Approval: Alectinib for the Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
    Clin Cancer Res. 2016 Jul 13. pii: clincanres.1293.2016.
    PubMed     Text format     Abstract available
    
    
    
93. CHONG CR, Bahcall M, Capelletti M, Kosaka T, et al
    Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.1601.2015.
    PubMed     Text format     Abstract available
    
    
    June 2016
94. WANG Y, Liu H, Diao L, Potter A, et al
    Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
    Clin Cancer Res. 2016 Jun 28. pii: clincanres.2190.2015.
    PubMed     Text format     Abstract available
    
    
    
95. GIRARD L, Rodriguez-Canales J, Behrens C, Thompson DM, et al
    An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 28. pii: clincanres.2900.2015.
    PubMed     Text format     Abstract available
    
    
    
96. YANAGITA M, Redig AJ, Paweletz CP, Dahlberg SE, et al
    A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.0909.2016.
    PubMed     Text format     Abstract available
    
    
    
97. WANG E, Nickens DJ, Bello A, Khosravan R, et al
    Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.0536.2016.
    PubMed     Text format     Abstract available
    
    
    
98. HAMILTON DH, Matthews Griner L, Keller JM, Hu X, et al
    Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.3059.2015.
    PubMed     Text format     Abstract available
    
    
    
99. GAPONOVA AV, Nikonova A, Deneka AY, Kopp MC, et al
    A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC).
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.3068.2015.
    PubMed     Text format     Abstract available
    
    
    
100. SIVA S, Lobachevsky PN, MacManus M, Kron T, et al
     Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues.
     Clin Cancer Res. 2016 Jun 3. pii: clincanres.0138.2016.
     PubMed     Text format     Abstract available
     
     
     
101. PARRA ER, Behrens C, Rodriguez-Canales J, Lin HY, et al
     Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients.
     Clin Cancer Res. 2016 Jun 1. pii: clincanres.2443.2015.
     PubMed     Text format     Abstract available
     
     
     
102. MORGENSZTERN D, Herbst RS
     Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2016 Jun 1. pii: clincanres.2998.2016.
     PubMed     Text format     Abstract available
     
     
     May 2016
103. GAINOR JF, Shaw AT, Sequist LV, Fu X, et al
     EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis.
     Clin Cancer Res. 2016 May 25. pii: clincanres.3101.2015.
     PubMed     Text format     Abstract available
     
     
     
104. TANG KJ, Constanzo J, Venkateswaran N, Melegari M, et al
     Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
     Clin Cancer Res. 2016 May 24. pii: clincanres.2603.2015.
     PubMed     Text format     Abstract available
     
     
     April 2016
105. NILSSON MB, Giri U, Gudikote J, Tang X, et al
     KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
     Clin Cancer Res. 2016;22:1940-50.
     PubMed     Text format     Abstract available
     
     
     
106. SHARMA A, Bender S, Zimmermann M, Riesterer O, et al
     Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2016 Apr 13. pii: clincanres.2449.2015.
     PubMed     Text format     Abstract available
     
     
     
107. DATAR I, Schalper KA
     Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
     Clin Cancer Res. 2016 Apr 13. pii: clincanres.0336.2016.
     PubMed     Text format     Abstract available
     
     
     
108. CORTOT AB, Moro-Sibilot D, Cadranel J
     Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter.
     Clin Cancer Res. 2016;22:1827.
     PubMed     Text format    
     
     
     March 2016
109. DRILON A
     MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
     Clin Cancer Res. 2016 Mar 23. pii: clincanres.0229.2016.
     PubMed     Text format     Abstract available
     
     
     
110. KAZANDJIAN D, Blumenthal GM, Yuan W, He K, et al
     FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2016;22:1307-12.
     PubMed     Text format     Abstract available
     
     
     February 2016
111. RODRIGUEZ PC, Popa X, Martinez O, Mendoza S, et al
     A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer Patients.
     Clin Cancer Res. 2016 Feb 29. pii: clincanres.0855.2015.
     PubMed     Text format     Abstract available
     
     
     
112. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
     Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
     Clin Cancer Res. 2016;22:923-34.
     PubMed     Text format     Abstract available
     
     
     
113. REDIG AJ, Capelletti M, Dahlberg SE, Sholl LM, et al
     Clinical and molecular characteristics of NF1 mutant lung cancer.
     Clin Cancer Res. 2016 Feb 9. pii: clincanres.2377.2015.
     PubMed     Text format     Abstract available
     
     
     
114. TONG JH, Yeung SF, Chan AW, Chung LY, et al
     MET amplification and exon 14 splice site mutation define unique molecular subgroups of Non-small Cell Lung Carcinoma with poor prognosis.
     Clin Cancer Res. 2016 Feb 4. pii: clincanres.2061.2015.
     PubMed     Text format     Abstract available
     
     
     
115. DIAZ-LAGARES A, Mendez-Gonzalez J, Hervas D, Saigi M, et al
     A novel epigenetic signature for early diagnosis in lung cancer.
     Clin Cancer Res. 2016 Feb 3. pii: clincanres.2346.2015.
     PubMed     Text format     Abstract available
     
     
     January 2016
116. TERASHIMA M, Togashi Y, Sato K, Mizuuchi H, et al
     Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2.
     Clin Cancer Res. 2016 Jan 29. pii: clincanres.2093.2015.
     PubMed     Text format     Abstract available
     
     
     
117. GREEN H, Hasmats J, Kupershmidt I, Edsgard D, et al
     Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
     Clin Cancer Res. 2016;22:366-73.
     PubMed     Text format     Abstract available
     
     
     
118. PIRAZZOLI V, Ayeni D, Meador CB, Sanganahalli BG, et al
     Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma.
     Clin Cancer Res. 2016;22:426-35.
     PubMed     Text format     Abstract available
     
     
     
119. TAO Z, Le Blanc JM, Wang C, Zhan T, et al
     Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
     Clin Cancer Res. 2016;22:122-33.
     PubMed     Text format     Abstract available
     
     
     December 2015
120. DRILON A, Somwar R, Wagner JP, Vellore NA, et al
     A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.
     Clin Cancer Res. 2015 Dec 16. pii: clincanres.2013.2015.
     PubMed     Text format     Abstract available
     
     
     
121. GOVINDAN R, Mandrekar SJ, Gerber DE, Oxnard GR, et al
     ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2015;21:5439-5444.
     PubMed     Text format     Abstract available
     
     
     
122. TSUI DW, Berger MF
     Profiling Non-Small Cell Lung Cancer: From Tumor to Blood.
     Clin Cancer Res. 2015 Dec 15. pii: clincanres.2514.2015.
     PubMed     Text format     Abstract available
     
     
     
123. BELL EH, Chakraborty AR, Mo X, Liu Z, et al
     SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer.
     Clin Cancer Res. 2015 Dec 15. pii: clincanres.1468.2015.
     PubMed     Text format     Abstract available
     
     
     
124. MANSFIELD AS, Murphy SJ, Peikert T, Yi ES, et al
     Heterogeneity of programmed cell death-ligand 1 expression in multifocal lung cancer.
     Clin Cancer Res. 2015 Dec 14. pii: clincanres.2246.2015.
     PubMed     Text format     Abstract available
     
     
     
125. GORGES TM, Penkalla N, Schalk T, Joosse S, et al
     Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells.
     Clin Cancer Res. 2015 Dec 14. pii: clincanres.1416.2015.
     PubMed     Text format     Abstract available
     
     
     
126. LEE JY, Sun JM, Lim SH, Kim H, et al
     A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
     Clin Cancer Res. 2015 Dec 14. pii: clincanres.1653.2015.
     PubMed     Text format     Abstract available
     
     
     
127. LI J, Ye C, Mansmann UR
     Comparing patient-derived xenograft and computational response prediction for targeted therapy in patients of early-stage large cell lung cancer.
     Clin Cancer Res. 2015 Dec 4. pii: clincanres.2401.2015.
     PubMed     Text format     Abstract available
     
     
     
128. IAFRATE AJ
     CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors.
     Clin Cancer Res. 2015;21:5185-7.
     PubMed     Text format     Abstract available
     
     
     November 2015
129. FERRAROTTO R, Goonatilake R, Yoo SY, Tong P, et al
     Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2015 Nov 23. pii: clincanres.2890.2014.
     PubMed     Text format     Abstract available
     
     
     June 2015
130. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
     Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
     Clin Cancer Res. 2015;21:2462-70.
     PubMed     Text format     Abstract available
     
     
     
131. CESCON DW, She D, Sakashita S, Zhu CQ, et al
     NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
     Clin Cancer Res. 2015;21:2499-505.
     PubMed     Text format     Abstract available
     
     
     
132. CHOI S, Kim HR, Sung CO, Kim J, et al
     Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma.
     Clin Cancer Res. 2015;21:2613-23.
     PubMed     Text format     Abstract available
     
     
     
133. COLLISSON EA
     RB and Prognosis in Resected Lung Adenocarcinoma.
     Clin Cancer Res. 2015;21:2418-20.
     PubMed     Text format     Abstract available
     
     
     May 2015
134. BATES SE
     Quit early, quit often.
     Clin Cancer Res. 2015;21:2212.
     PubMed     Text format    
     
     
     April 2015
135. ARCILA ME, Drilon A, Sylvester BE, Lovly CM, et al
     MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
     Clin Cancer Res. 2015;21:1935-43.
     PubMed     Text format     Abstract available
     
     
     March 2015
136. STARMANS MH, Pintilie M, Chan-Seng-Yue M, Moon NC, et al
     Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
     Clin Cancer Res. 2015;21:1477-86.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: